Podcasts about preclinical

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract  Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract  Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.  Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.  Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

Dr. Dustin Sulak Home Healer Certification-BH Sales Kennel Kelp Holistic Healing Hour: Unlocking the Potential of Cannabinoids for Autism SupportOne area of exciting research involves the impact of cannabinoids – those fascinating compounds found in cannabis – on individuals with ASD. A study examining salivary biomarkers revealed that THC, CBD, and CBG each tend to influence distinct sets of these biological markers. This suggests that different cannabinoids might exert unique effects on the body's systems.Intriguingly, research has also indicated that some children with autism present with lower levels of certain circulating endocannabinoids – specifically AEA, OEA, and PEA. These are our body's own cannabis-like molecules, playing crucial roles in regulating various functions.A compelling 2019 Israeli study looked at children with autism who didn't initially respond to a THC:CBD ratio of 1:20. Interestingly, a significant number of these children showed better outcomes when their treatment was switched to a THC:CBD ratio of 1:6. This underscores the importance of finding the right balance and individualizing treatment.Grandpa Bill: So, as we digest these fascinating insights, two probing questions come to mind:Given the variability of ASD and the distinct impacts of different cannabinoids, how can we best personalize cannabinoid-based approaches to optimize individual outcomes?With limited FDA-approved medications for core autism symptoms, what further research is needed to rigorously evaluate the safety and efficacy of various cannabinoid ratios and combinations? #AutismSupport #Cannabinoids #HolisticHealing ,#Endo cannabinoid System,It's crucial to acknowledge that only two medications have received FDA approval to address the core symptoms of autism, underscoring the need for continued exploration of complementary approaches.Preclinical research also offers valuable insights. A rodent model of ASD showed that inhibiting the FAAH enzyme, which breaks down endocannabinoids, led to improvements in repetitive and compulsive behaviors. CBD is considered the most likely cannabinoid to replicate this mechanism.However, caution is warranted. High-dose CBD treatments have been associated with adverse effects, particularly in individuals with low appetite, low body weight, or increased sedation. Personalized dosing and careful monitoring are paramount.The "core symptoms" of autism often involve challenges in social communication and interaction, as well as restricted and repetitive behaviors. Interestingly, a specific study indicated that CBD-dominant treatment led to improvements in pica, the dangerous compulsion to consume non-food items.The research landscape surrounding cannabinoids and ASD is evolving rapidly. Key questions remain:How can we leverage the unique properties of different cannabinoids to create highly personalized interventions for individuals across the autism spectrum?What rigorous, large-scale clinical trials are necessary to definitively establish the safety and efficacy of various cannabinoid formulations for ASD?The journey of understanding and supporting individuals with ASD is complex and multifaceted. The potential of cannabinoids offers a promising avenue for exploration, but it must be approached with careful research, individualized strategies, and ongoing collaboration between researchers, clinicians, and the autism community, which over stating the OBVIOUS it is here!#AutismSpectrumDisorder #ASD #Cannabinoids #CBD ,#THC, #CBG, #EndocannabinoidSystem, #HolisticHealth, #Dr.DustinSulak ,#Research, #Neurodiversity, #BHSalesKennelKelpHolisticHealingHour ,#GrandpaBillsWisdom,

The potential of pluripotent stem cells and the ability to scale and differentiate them to generate large numbers of enriched cell populations has created new opportunities and approaches to treat human disease. Preclinical proof-of-principle data demonstrates that stem cell-derived neural grafts can be used to reverse symptoms of multiple neurological conditions, including Parkinson's Disease. Cell grafts enriched with dopaminergic neurons, can structurally and functionally integrate in the brain of Parkinson's Disease models to reverse motor deficits, a finding which has launched several clinical trials. While the results in animal models is essential proof-of-concept, the survival and integration of these cells is suboptimal compared to treatments from fetal-derived ventral midbrain grafts.  An area of preclinical and clinical research showing promise in influencing neuronal survival and plasticity is exercise. The benefits of exercise on neural function and disease progression have been widely reported and they have also been shown to enhance the survival and integration of transplanted cells in models of some neurological diseases. However, there is limited data on the benefit of exercise on the functional outcomes of neural grafts in Parkinson's Disease models. The guests on today's program will discuss their recent study looking at the effect of exercise on cellular engraftment and functional recovery in animal models of Parkinson's Disease and the implications for clinical outcomes. GuestsClare Parish, PhD, The Florey Institute of Neuroscience and Mental Health and University of Melbourne, Australia Niamh Moriarty, PhD, The Florey Institute of Neuroscience and Mental Health and University of Melbourne, AustraliaSupporting ContentPaper link: Exercise promotes the functional integration of human stem cell-derived neural grafts in a rodent model of Parkinson's disease HostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Senior Marketing ManagerJack Mosher, Scientific AdvisorHunter Reed, Senior Marketing Coordinator

Roadmap for Medical Device Startups Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. The path for a medical device startup is clearly defined. In building a medical device startup or diligencing one, consider this roadmap. Market requirements -- establish the current state of the market, including size, needs, and current solutions. Product requirements -- define the requirements a medical device product must have to be successful with customers. Clinical unit -- a prototype that is used to run initial clinical tests. Preclinical validation -- initial test results with the clinical unit. First in human test -- clinical trials with human subjects. Clinical validation -- in human clinical test results. CE Mark -- regulatory approval to sell a product in Europe. First European orders -- initial sales of the product in Europe 510 K clearance -- regulatory approval to sell the clinical device in the US. First US orders -- initial sales of the product in the US. Break even -- sales equal operating costs. Growth then scale -- sales continue to grow. In reviewing a medical device startup, it's important to know the steps ahead and plan your fundraising for it.   Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

In this JCO PO Article Insights episode, host Harold Tan summarizes Low Kynurenine Levels Among Exceptional Responders on Phase Ib Trial of the HDAC Inhibitor Abexinostat with Pazopanib by Tsang et al, published November 07, 2024. Transcript Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights, where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host, and today we're taking a focused look at a compelling phase Ib trial led by Dr. Tsang, which investigates a combination of abexinostat, a histone deacetylase inhibitor, with pazopanib, a VEGF-targeting tyrosine kinase inhibitor, in patients with advanced solid tumors. VEGF inhibition has long been an established therapeutic strategy across a wide range of tumor types, including colorectal, ovarian, sarcoma, and renal cell carcinoma. These agents function by disrupting tumor angiogenesis, effectively limiting oxygen and nutrient delivery to malignant cells and contributing to improved survival outcomes. However, over time, acquired resistance remains a significant challenge. A key mechanism implicated in this resistance involves the upregulation of hypoxia-inducible factor 1-alpha, or HIF-1-alpha for short, a master regulator of angiogenesis that restores VEGF signaling under hypoxic conditions. Interestingly, HIF-1-alpha overexpression is mediated by histone deacetylases, especially HDAC2. Preclinical studies suggest that HDAC2 inhibition can suppress tumor cell migration and downregulate HIF-1-alpha activity, effectively disabling a critical escape pathway used by tumors under VEGF pressure. Moreover, combining HDAC inhibition with VEGF blockade has demonstrated synergy in pazopanib-resistant tumor models, forming a compelling rationale for this dual approach. The phase Ib trial by Tsang et al. was designed to evaluate the safety, tolerability, and preliminary efficacy of this dual-targeted approach in patients with heavily pretreated advanced solid tumors. A dose-expansion cohort focused on individuals with renal cell carcinoma, allowing for more detailed evaluation in this population. A central component of this study was the incorporation of biomarker analysis, particularly regarding HDAC2 expression levels. The results were noteworthy. Patients with high HDAC2 expression achieved a progression-free survival of 7.7 months compared to only 3.5 months in those with low expression. Even more compelling, overall survival reached 32.3 months for those with a high HDAC2 expression versus just 9.2 months for those with low expression. This suggests the potential role for HDAC2 as a predictive biomarker for response to combination HDAC and VEGF-targeted therapy. The authors also explored the metabolic landscape of these patients, conducting metabolomic analysis focused on kynurenine, a key tryptophan catabolite known to contribute to the immune suppression in the tumor microenvironment. Its reduction is driven by HIF-1-alpha and inflammatory cytokines, including interleukin-6 and tumor necrosis factor-alpha. What they found was striking. Exceptional responders, defined as patients with treatment responses lasting more than 3 years, had consistently lower levels of kynurenine both before and after treatment. This finding introduces kynurenine as a potential metabolic biomarker. It suggests that patients with lower kynurenine levels may have a less immunosuppressive microenvironment, making them more responsive to the combined effects of HDAC inhibition and VEGF blockade. Of note, VEGF levels themselves did not significantly differ between responders and nonresponders, highlighting that the treatment benefit is not purely VEGF-mediated but likely driven by epigenetic and metabolic modulation. On the safety front, the combination of abexinostat and pazopanib was generally well tolerated. However, this study did report a correlation between higher plasma concentrations of abexinostat and an increased incidence of thrombocytopenia, a class effect associated with HDAC inhibitors. This trial introduces several key considerations for future research. First, it calls for validation of HDAC2 as a predictive biomarker. If confirmed in larger cohorts, HDAC2 expression could be used to select patients most likely to benefit from HDAC inhibitor-based regimens, transforming how we approach trial enrollment and treatment planning. Second, the link between low kynurenine and exceptional response supports further investigation into how metabolic pathways can influence treatment response to combined HDAC and VEGF inhibition. Overall, HDAC inhibitors hold significant promise in precision oncology. Realizing their full therapeutic potential requires a deeper understanding of HDAC biology, refined combination strategies, and thorough preclinical and clinical evaluations tailored to individual patient profiles. This study exemplifies the potential of epigenetic-metabolic crosstalk as a therapeutic vulnerability and underscores the importance of precision stratification in clinical trial design. As research in this space progresses, the integration of molecular, epigenetic, and metabolic profiling will be essential in optimizing the use of HDAC inhibitors and expanding their role within precision oncology. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

BUFFALO, NY - April 4, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT." Researchers from Brown University, led by first author Lanlan Zhou and corresponding author Wafik S. El-Deiry, have shown that combining a new class of drugs called imipridones with standard glioblastoma treatments significantly improves outcomes in mice. The study tested ONC201 and its analog ONC206 in combination with radiation therapy and the chemotherapy drug temozolomide (TMZ), a regimen referred to as IRT. This triple therapy slowed tumor growth and extended survival in a mouse model of glioblastoma, offering a potential new strategy for one of the most aggressive and treatment-resistant brain cancers. Glioblastoma is a fast-growing brain tumor with a poor prognosis and limited treatment options. Standard care typically includes surgery, radiation, and TMZ, but most patients still face a short life expectancy. While ONC201 and ONC206 are currently being studied in clinical trials as single agents, there has been limited information on how they interact with standard therapies. This study is the first to show that both drugs work synergistically with radiation and TMZ, strengthening their overall effects. The results showed that in both laboratory-grown tumor cells and mice, the triple therapy significantly slowed cancer cell growth, reduced tumor size, and prolonged survival compared to using any single or double treatment. Mice treated with IRT lived an average of 123 days, with some surviving more than 200 days—far longer than the 44 to 103 days observed with other treatment combinations. In addition to directly killing tumor cells, ONC201 and ONC206 lowered the expression of MGMT, a protein that helps tumors resist chemotherapy, making the treatment more effective. The researchers also found that the triple therapy reshaped the tumor environment. It decreased levels of harmful molecules that promote tumor growth and immune evasion while increasing signals that activate the immune system. This dual action—directly attacking tumors and boosting immune responses—adds to the potential impact of this treatment approach. “Overall, our preclinical findings support further exploration of the ONC201 and ONC206 IRT regimen as a potential treatment for GBM and diffuse gliomas with H3K27M mutations.” While these findings are based on preclinical mouse models, they offer strong support for advancing this triple therapy to clinical trials. ONC201 and ONC206 are promising due to their ability to cross the blood-brain barrier and enhance the effects of standard treatment. This combination could lead to more effective therapies for glioblastoma and other hard-to-treat brain tumors. DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.

Introducing Part 4 – New Frontiers in AI & Drug Discovery from Science Will Win.Follow the show: Science Will WinSo far in this season, we've explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we're looking toward the future, to understand where today's advancements could potentially take us. Featured Guests:–Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer–Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It's produced by Wonder Media Network. DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to team@podroll.fm.

Introducing Part 4 – New Frontiers in AI & Drug Discovery from Science Will Win.Follow the show: Science Will WinSo far in this season, we've explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we're looking toward the future, to understand where today's advancements could potentially take us. Featured Guests:–Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer–Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It's produced by Wonder Media Network. DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to team@podroll.fm.

Introducing Part 4 – New Frontiers in AI & Drug Discovery from Science Will Win.Follow the show: Science Will WinSo far in this season, we've explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we're looking toward the future, to understand where today's advancements could potentially take us. Featured Guests:–Charlotte Allerton, Head of Preclinical and Translational Sciences at Pfizer–Daniel Ziemek, Vice President of Integrative Biology and Systems Immunology at Pfizer–Enoch Huang, Head of Machine Learning and Computational Sciences at Pfizer–Dr. Raza Ali, group leader at the University of Cambridge Cancer Research UK Institute, pathologist Season 4 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It's produced by Wonder Media Network. DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to team@podroll.fm.

Season 2 Episode 1 (February 14, 2025): This week, the GEN editors discussed some interesting and developing stories around AI, including an in depth dialogue about what Recursion has been doing lately. They also discussed gene editing updates in delivery systems, Cas12 preclinical work, and AgBio. The discussion was rounded out with a look forward into takeover targets for 2025. Featuring Alex Philippidis (Senior Business Editor, GEN), Fay Lin, PhD, (Editor, GEN Biotechnology), Uduak Thomas (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM) Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base: As Pipeline Advances, Recursion Expands AI Focus to Clinical TrialsBy Alex Phillipidis, GEN, Jan 30, 2025. Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain DiseaseBy Fay Lin, PhD, GEN Edge, Feb 5, 2025. AAV Delivered NanoCas CRISPR System Edits Muscle in Non-Human PrimatesBy GEN, Feb 3, 2025. Next-Gen Cas12a System Enables Precise Single and Multiplexed Gene Editing in CancerBy Corinna Singleman, PhD, GEN, Jan 30, 2025. AgBio Companies Embrace Gene Editing for Stronger Food FutureBy Uduak Thomas, GEN Feb issue, Feb 3, 2025. Top 10 Takeover Targets of 2025By Alex Phillippidis, GEN, Feb 3, 2025. Hosted on Acast. See acast.com/privacy for more information.

Degenerative or myxomatous mitral valve disease (MMVD) is a common canine cardiac disease. In this episode of the VetFolio Voice podcast, we discuss the importance of early diagnosis and treatment in order to slow the progression of this disease. Listen in as we chat about MMVD, from diagnosis through the preclinical stages of the disease. We review diagnostics that can be helpful in assessing this disease, such as thoracic radiographs and echocardiography, and what information can be obtained from each. We'll also explore how the treatment plan may change once the patient is symptomatic. Want to earn CE from this episode? Be sure to log into VetFolio and take the quiz to qualify for your CE credit! https://www.vetfolio.com/courses/treatment-of-preclinical-mitral-valve-disease-in-your-practice-podcast-quiz

In this episode of Let's Combinate, host Subhi Sadeh is joined by Marta New, CEO of Radyus Research, to discuss the importance of Target Product Profiles (TPPs) in drug development and combination products. Marta, with her unique background as a venture capitalist turned CRO founder, shares her insights on how TPPs serve as strategic documents that align clinical goals, regulatory requirements, and market strategies. The discussion delves into the key sections of a TPP, such as target indication, efficacy benchmarks, safety and toxicology, and regulatory strategy. Marta emphasizes the critical role of TPPs in preclinical stages and their impact on the overall success of drug development programs. The episode also explores the integration and collaboration required across various functions like R&D, quality, regulatory, and commercial teams to create and refine a robust TPP.00:00 Introduction and Welcome00:26 Meet Marta: CEO of Radius Research00:58 Understanding Target Product Profiles (TPPs)01:44 The Importance of TPPs in Drug Development01:59 Defining a TPP03:22 TPP as a Strategic Document05:28 TPP in Preclinical and Clinical Stages07:09 Challenges and Misconceptions in TPP Development14:27 Regulatory Considerations for TPPs14:53 Sections of a TPP39:07 Understanding Toxicology Evaluations39:34 FDA Requirements for Pre-IND Talks39:51 TPP and Toxicity Thresholds41:41 Go/No-Go Criteria in TPP42:50 PKPD and Drug Distribution45:40 Drug Formulation and Quality Attributes46:36 Regulatory Strategy and 505(b)(2) Pathway52:34 Differentiation and Risk Assessment01:03:42 Transition from Discovery to Development01:07:48 Combination Products and Delivery Systems01:09:35 Conclusion and Contact InformationMarta New PhD MBA is the CEO of Radyus Research. She is an experienced drug developer with a background in early-stage venture capital, considerable pharma R&D, and university technology transfer. She can be reached at mnew@radyusresearch.com

In today's VETgirl online veterinary CE podcast, we're going to talk about one of my favorite breeds, the super sweet Cavalier King Charles Spaniel (what we'll Cavaliers from now on, since it's a mouthful!). Unfortunately, we all know that this breed has horrible myxomatous mitral valve disease. So, if you see Cavaliers in your clinic, when should you decide to put these dogs on heart medications? After all, we know that the initiation of pimobendan can significantly delay the onset of congestive heart failure in dogs with stage B2 myxomatous mitral valve disease (or “mitral valve disease”), and that detection of the transition from stage B1 to B2 in this population of dogs is important so that therapy can be initiated expediently.Sponsored By: Antech

Silo Pharma CEO Eric Weisblum joined Steve Darling from Proactive to discuss the company's positive findings from a preclinical study on its novel dual-target formulation designed to address major depressive disorder and severe stress-related conditions. Weisblum highlighted the promising potential of the treatment to deliver enhanced outcomes by combining two therapeutic approaches. The study revealed that this formulation, which simultaneously targets two key pathways linked to mood and stress regulation, demonstrated superior effectiveness in reducing stress-induced behaviors compared to treatments focusing on a single pathway. Animal models showed notable improvements in behavioral outcomes, suggesting the approach could be particularly effective in managing severe psychiatric challenges. Weisblum shared that the formulation is being explored as a potential intranasal preventative treatment for post-traumatic stress disorder (PTSD). The company is now preparing for an Investigational New Drug (IND) submission to progress to human clinical trials. “This study validates our innovative dual-target approach,” Weisblum stated. “By addressing two critical mechanisms simultaneously, we aim to set a new benchmark in care for patients struggling with debilitating stress-related conditions.” Silo Pharma's advancements reflect its dedication to developing groundbreaking solutions for complex psychiatric disorders. The company is optimistic about transitioning its research into clinical development to meet the urgent need for improved mental health treatments. #proactiveinvestors #silopharmainc #nasdaq #silo #BiotechNews #SPC15 #PTSDTreatment #ChronicPain #Fibromyalgia #FDAApproval #EricWeisblum #PharmaUpdates #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Amplia Therapeutics Ltd (ASX: ATX) CEO and managing director Chris Burns​​​​ joins Proactive's Tylah Tully to discuss a preclinical research collaboration the company has entered into with Next&Bio, a drug screening company based in Seoul, South Korea. This collaboration aims to evaluate the effects of Amplia's focal adhesion kinase (FAK) inhibitors in combination with kRas inhibitors, a class of drugs under development for pancreatic cancer treatment. Next&Bio, a subsidiary of Hk Kolmar Holdings, specialises in drug screening using patient-derived cancer cells cultivated under conditions that replicate the tumour environment. These models allow accurate testing of potential drug efficacy, particularly in pancreatic cancer cases with oncogenic mutations. The collaboration will test Amplia's FAK inhibitors, such as narmafotinib (AMP945), against pancreatic cancer cells harbouring kRas mutations. Narmafotinib, Amplia's selective and potent FAK inhibitor, is currently in a Phase 2a trial evaluating its safety and efficacy in combination with gemcitabine and Abraxane®. The collaboration also investigates potential synergistic effects with kRas inhibitors, which could open new therapeutic opportunities for pancreatic cancer. Burns highlighted the significance of testing the company's FAK inhibitors in patient-derived cell systems to explore new commercial applications for combination therapies in pancreatic cancer. #ProactiveInvestors #AmpliaTherapeutics #ASX #NextAndBio #FAKInhibitors #PancreaticCancer #DrugDevelopment #OncologyResearch #kRasInhibitors #CancerTherapy #Narmafotinib #PrecisionMedicine #CancerCells #Amplia #CancerResearch #ClinicalTrials #ASXNews #Pharmaceuticals #OncogeneResearch #MedicalInnovation #FAK #TargetedTherapy

En el episodio de hoy, tratamos de responder a la pregunta que formulamos, sobre todo matizando la autonomía o no de esos CPGs en la médula humana. Revisamos los principales autores y estudios sobre el tema y ahondamos en la evidencia más actual sobre el sistema de interneuronas que conforman los CPGs y las implicaciones para la neurorrehabilitación (estimulación epidural y terapia intensiva). Referencias del episodio: 1. Angeli, C. A., Edgerton, V. R., Gerasimenko, Y. P., & Harkema, S. J. (2014). Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans. Brain : a journal of neurology, 137(Pt 5), 1394–1409. https://doi.org/10.1093/brain/awu038 (https://pubmed.ncbi.nlm.nih.gov/24713270/). 2. Barkan, C. L., & Zornik, E. (2019). Feedback to the future: motor neuron contributions to central pattern generator function. The Journal of experimental biology, 222(Pt 16), jeb193318. https://doi.org/10.1242/jeb.193318 (https://pmc.ncbi.nlm.nih.gov/articles/PMC6739810/). 3. Brown, T. G. (1911). The Intrinsic Factors in the Act of Progression in the Mammal. Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 84(572), 308–319. http://www.jstor.org/stable/80647 (https://www.jstor.org/stable/80647). 4. Cherni, Y., Begon, M., Chababe, H., & Moissenet, F. (2017). Use of electromyography to optimize Lokomat® settings for subject-specific gait rehabilitation in post-stroke hemiparetic patients: A proof-of-concept study. Neurophysiologie clinique = Clinical neurophysiology, 47(4), 293–299. https://doi.org/10.1016/j.neucli.2017.01.008 (https://pubmed.ncbi.nlm.nih.gov/28318816/). 5. Courtine, G., Gerasimenko, Y., van den Brand, R., Yew, A., Musienko, P., Zhong, H., Song, B., Ao, Y., Ichiyama, R. M., Lavrov, I., Roy, R. R., Sofroniew, M. V., & Edgerton, V. R. (2009). Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. Nature neuroscience, 12(10), 1333–1342. https://doi.org/10.1038/nn.2401 (https://pubmed.ncbi.nlm.nih.gov/19767747/). 6. Dietz V. (2010). Behavior of spinal neurons deprived of supraspinal input. Nature reviews. Neurology, 6(3), 167–174. https://doi.org/10.1038/nrneurol.2009.227 (https://pubmed.ncbi.nlm.nih.gov/20101254/). 7. Dimitrijevic, M. R., Gerasimenko, Y., & Pinter, M. M. (1998). Evidence for a spinal central pattern generator in humans. Annals of the New York Academy of Sciences, 860, 360–376. https://doi.org/10.1111/j.1749-6632.1998.tb09062.x (https://pubmed.ncbi.nlm.nih.gov/9928325/). 8. Dzeladini, F., van den Kieboom, J., & Ijspeert, A. (2014). The contribution of a central pattern generator in a reflex-based neuromuscular model. Frontiers in human neuroscience, 8, 371. https://doi.org/10.3389/fnhum.2014.00371 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4071613/). 9. Gizzi, L., Nielsen, J. F., Felici, F., Moreno, J. C., Pons, J. L., & Farina, D. (2012). Motor modules in robot-aided walking. Journal of neuroengineering and rehabilitation, 9, 76. https://doi.org/10.1186/1743-0003-9-76 (https://pubmed.ncbi.nlm.nih.gov/23043818/). 10. Gosgnach S. (2022). Synaptic connectivity amongst components of the locomotor central pattern generator. Frontiers in neural circuits, 16, 1076766. https://doi.org/10.3389/fncir.2022.1076766 (https://pmc.ncbi.nlm.nih.gov/articles/PMC9730330/). 11. Grillner, S. (1981). Control of Locomotion in Bipeds, Tetrapods, and Fish. Comprehensive Physiology, 1179-1236 (https://onlinelibrary.wiley.com/doi/10.1002/cphy.cp010226). 12. Guertin P. A. (2014). Preclinical evidence supporting the clinical development of central pattern generator-modulating therapies for chronic spinal cord-injured patients. Frontiers in human neuroscience, 8, 272. https://doi.org/10.3389/fnhum.2014.00272 (https://pubmed.ncbi.nlm.nih.gov/24910602/). 13. Harkema, S., Gerasimenko, Y., Hodes, J., Burdick, J., Angeli, C., Chen, Y., Ferreira, C., Willhite, A., Rejc, E., Grossman, R. G., & Edgerton, V. R. (2011). Effect of epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study. Lancet (London, England), 377(9781), 1938–1947. https://doi.org/10.1016/S0140-6736(11)60547-3 (https://pubmed.ncbi.nlm.nih.gov/21601270/). 14. Kathe, C., Skinnider, M. A., Hutson, T. H., Regazzi, N., Gautier, M., Demesmaeker, R., Komi, S., Ceto, S., James, N. D., Cho, N., Baud, L., Galan, K., Matson, K. J. E., Rowald, A., Kim, K., Wang, R., Minassian, K., Prior, J. O., Asboth, L., Barraud, Q., … Courtine, G. (2022). The neurons that restore walking after paralysis. Nature, 611(7936), 540–547. https://doi.org/10.1038/s41586-022-05385-7 (https://pubmed.ncbi.nlm.nih.gov/36352232/). 15. Minassian, K., Jilge, B., Rattay, F., Pinter, M. M., Binder, H., Gerstenbrand, F., & Dimitrijevic, M. R. (2004). Stepping-like movements in humans with complete spinal cord injury induced by epidural stimulation of the lumbar cord: electromyographic study of compound muscle action potentials. Spinal cord, 42(7), 401–416. https://doi.org/10.1038/sj.sc.3101615 (https://pubmed.ncbi.nlm.nih.gov/15124000/). 16. Minassian, K., Persy, I., Rattay, F., Dimitrijevic, M. R., Hofer, C., & Kern, H. (2007). Posterior root-muscle reflexes elicited by transcutaneous stimulation of the human lumbosacral cord. Muscle & nerve, 35(3), 327–336. https://doi.org/10.1002/mus.20700 (https://pubmed.ncbi.nlm.nih.gov/17117411/). 17. Radhakrishna, M., Steuer, I., Prince, F., Roberts, M., Mongeon, D., Kia, M., Dyck, S., Matte, G., Vaillancourt, M., & Guertin, P. A. (2017). Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury. Current pharmaceutical design, 23(12), 1789–1804. https://doi.org/10.2174/1381612822666161227152200 (https://pubmed.ncbi.nlm.nih.gov/28025945/). 18. Reier, P. J., Howland, D. R., Mitchell, G., Wolpaw, J. R., Hoh, D., & Lane, M. A. (2017). Spinal cord injury: repair, plasticity and rehabilitation. eLS, 1-12 (https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0021403.pub2).

Candel Therapeutics Chief Scientific Officer Dr. Francesca Barone joined Steve Darling from Proactive to share news the company is presenting at the Society for Immunotherapy of Cancer (SITC) conference. Barone, the company's Chief Scientific Officer shared details on CAN-3110, a first-in-class oncolytic viral therapy designed to selectively replicate within cancer cells. CAN-3110 is engineered to minimize effects on healthy cells while triggering a potent immune response within tumors, a promising innovation for treating difficult cancers like recurrent high-grade glioma and resistant melanoma. “Immunotherapy has transformed melanoma treatment, but many patients remain resistant,” Dr. Barone explained. Preclinical melanoma data shows CAN-3110 significantly reduces tumor burden while activating the immune system in cell models. The therapy's success in melanoma trials also hints at broader applications, with Dr. Barone citing potential future investigations into triple-negative breast cancer and sarcoma. With a strong safety profile, Candel Therapeutics is now considering targeted preclinical trials to assess CAN-3110's impact across additional challenging cancers. This novel therapeutic could offer new hope for patients with limited options, potentially transforming treatment landscapes for resistant tumor types. #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Dr. Reisa Sperling returns for another episode of Dementia Matters. After covering her research focused on preclinical Alzheimer's disease in part one, Dr. Sperling dives deeper into the different factors that can impact cognitive decline and early-stage Alzheimer's disease and how clinical trials are shaping the field's understanding of detecting, treating and preventing the disease. Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer's Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School   Show Notes Listen to our first episode with Dr. Sperling, “Defining and Addressing Preclinical Alzheimer's Disease,” on Spotify, Apple Podcasts and on our website. Read more about the Harvard Aging Brains Study on their website. Read more about the AHEAD Study on their website. Watch “Voices from the AHEAD Alzheimer's Disease Trial,” featuring Dr. Cynthia Carlsson and a research participant, on YouTube.  Learn more about the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) study here. Learn more about Dr. Sperling in her profile on the Massachusetts General Hospital website.   Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

While some of us knew a good bit about mRNA prior to 2020, we all got a crash course on mRNA technology and its prophylactic and therapeutic potential as a result of the COVID pandemic and subsequent SARS CoV-2 vaccine development. In fact, most of us have now received at least one mRNA vaccine at this point. Our guest for this episode, Dr. Christian Cobaugh, Co-founder and CEO of Vernal Biosciences, was a passionate believer in mRNA medicines well before the pandemic. Join us to hear his story and his passion for this technology. He walks us through the molecular methods by which high-purity mRNAs are now made and purified, as well as going into the lipid nanoparticle technology by which they're commonly delivered. As a contract development and manufacturing provider, we get to learn about the state of the market and what clients of their care about today. As a seasoned expert in this space, Christian talks about the future potential of mRNA technology for applications such as personalized cancer vaccines. If you enjoy hearing smart people talk about interesting topics with a passion, you won't want to miss this episode! Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Download Transcripts: Speaking of Mol Bio Podcast | Thermo Fisher Scientific - US Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology.

What if there was a way to detect Alzheimer's disease before clinical signs and symptoms even appeared? Dr. Reisa Sperling joins Dementia Matters for a two-part series covering her research on detecting and treating Alzheimer's disease at the earliest possible stage, known as preclinical Alzheimer's. In this episode, Dr. Sperling goes in-depth on amyloid and tau proteins and the implications on early detection and treatment strategies forAlzheimer's disease. Guest: Reisa Sperling, MD, director, Center for Alzheimer Research and Treatment (CART), co-principal investigator, Harvard Aging Brain Study, principal investigator, Alzheimer's Clinical Trials Consortium (ACTC), co-leader, A4 Study, co-leader, AHEAD 3-45 Study, professor of neurology, Harvard Medical School   Show Notes Read more about the Harvard Aging Brains Study on their website. Read more about the AHEAD Study on their website. Watch “Voices from the AHEAD Alzheimer's Disease Trial,” featuring Dr. Cynthia Carlsson and a research participant, on YouTube.  Learn more about the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) study here. Learn more about Dr. Sperling in her profile on the Massachusetts General Hospital website.   Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share its lead drug formulation, Ruvidar, has shown significant preclinical effectiveness in destroying the Herpes Simplex Virus 1 (HSV-1), surpassing the current standard of care, Acyclovir. Acyclovir, widely used to manage HSV-1, does not cure the virus but helps to alleviate symptoms associated with herpes infections, such as cold sores, genital herpes, shingles, and chicken pox. DuMoulin-White highlighted that the global antiviral drug market is projected to reach around $71 billion by 2032, with approximately 3.7 billion people under age 50 infected with HSV-1. The preclinical findings indicate that Ruvidar is not only more potent than Acyclovir but also capable of preventing HSV-1 replication by an impressive 10 million-fold if administered one day post-infection—something Acyclovir fails to achieve. These promising results position Ruvidar as a potential game-changer in the treatment of HSV-1, offering hope for more effective management of this widespread virus. #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #proactiveinvestors #theralasetechnologiesinc #tsxv #tlt #otcqb #tftff #MedicalResearch #HealthcareInnovation #PatientCare #CancerResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #Ruvidar #Acyclovir #Pharmaceuticals #Biotech #Oncology #ViralInfections #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Send us a Text Message.Today my guest is Danielle Brown, a fellow veterinary pathologist, the General Manager at Charles River Laboratories Reno, Nevada, and a pioneer in the use of image analysis for toxicologic pathology. Together, we explored the ever-evolving role of image analysis in preclinical studies and how it enhances, rather than replaces, the expertise of pathologists.This conversation is a deep dive into the intersection of pathology and technology, showcasing how image analysis is revolutionizing preclinical research. We also discuss the future of this technology and its implications for the industry.Join us as we navigate the intricacies of image analysis, share insights on the collaborative process between pathologists and image analysis scientists, and look ahead to the exciting advancements on the horizon.Key Discussion Points:[00:00:00] Introduction and Guest Welcome:Introducing Danielle Brown and her significant contributions to the field of toxicologic pathology.[00:02:46] The Role of Image Analysis in Preclinical Drug Development:Why image analysis is crucial for accurate and efficient evaluations in preclinical studies.[00:03:23] Challenges and Limitations of Visual Analysis:Discussing the limitations of visual analysis and how image analysis overcomes these challenges.[00:08:06] Pathologist and Image Analysis Collaboration:The importance of collaboration between pathologists and image analysis scientists to ensure accurate data interpretation.[00:13:00] Efficiency and Cost of Image Analysis vs. Pathologist Scoring:Comparing the efficiency, cost, and consistency between image analysis and traditional pathologist scoring methods.[00:15:18] Validation and Qualification of Image Analysis Algorithms:The process of validating image analysis algorithms to ensure they meet regulatory standards in a GLP environment.[00:19:54] GLP Compliance and Regulatory Considerations:How Charles River ensures GLP compliance in their image analysis processes, making them suitable for regulatory submissions.[00:23:27] Method Development for Specific Stains and Techniques:Approaching projects that require new method development or specialized procedures.[00:27:46] Future of Image Analysis in Pathology:Danielle's insights into the future of image analysis and how emerging technologies will shape the field.This episode is packed with valuable insights and practical advice for anyone involved in preclinical research or interested in the integration of image analysis in pathology. Danielle's expertise and our discussion provide a roadmap for leveraging image analysis to increase evaluation efficiency and the granularity of your data.THIS EPISODE'S RESOURCES:

The pipeline of antibiotic discovery is a major necessity due to the continuous evolution of resistance to currently used antimicrobials. This pipeline faces important challenges due to the lack of investment on antimicrobial research in the private sector and an economic model that discourages investment. In the last few years, however, encouraging signs are occurring but major gaps still remain. The World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline and the latest report is now available in the journal, lets discuss it! Watch this episode: https://youtu.be/IgqWmHDIx-0 Topics discussed: The process for review of the antibacterial pipeline. The progress and gaps in antibiotic discovery The opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space Guest: Valeria Gigante Ph.D., Team Lead at the World Health Organization's (WHO) in the AMR Division, Geneva, Switzerland. Link: Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps. This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up. Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/dementia-on-a-spectrum-preclinical-stages-of-mci-in-ad/26339/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer's disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer's disease.

Lisata Therapeutics Inc chief medical officer Kristen Buck joined Proactive's Stephen Gunnion to discuss encouraging preclinical results for drug candidate certepetide in treating intrahepatic cholangiocarcinoma (bile duct cancer). Buck explained that the study involved a mouse model with orthotopically implanted cholangiocarcinoma, separated into four treatment groups: a control group, a group receiving only certepetide, a group treated with gemcitabine, cisplatin, and anti-PD-1 immunotherapy, and a group receiving certepetide in combination with the chemotherapy and immunotherapy. The results demonstrated that certepetide significantly enhanced the effects of chemotherapy and immunotherapy, prolonging survival, reducing lung metastases, and decreasing comorbidities like ascites. Buck highlighted that certepetide targets two specific receptors upregulated on solid tumors and helps transform the fibrotic stromal barrier in cholangiocarcinoma into a conduit for chemotherapy and immunotherapy, improving drug penetration into the tumor. These promising preclinical results come on top of the ongoing BOLSTER trial, a Phase 2a study evaluating certepetide in humans with first-line cholangiocarcinoma and a secondary cohort for second-line treatment. "We believe that using our drug in combination with immunotherapy will demonstrate a significant benefit," says Buck. "Certepetide not only targets and penetrates tumors but also modifies the hostile tumor microenvironment, decreasing T regulatory cells and increasing cytotoxic T-cells to help kill cancer." For more insightful videos like this, visit Proactive's YouTube channel. Don't forget to give the video a like, subscribe to our channel, and enable notifications for future content. #LisataTherapeutics #CancerResearch #Certepetide #Cholangiocarcinoma #CancerTreatment #Immunotherapy #PreclinicalResults #Oncology #MedicalResearch #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The FDA Group's Nick Capman sits down with Carlos Yuraszeck, an accomplished leader in biopharmaceutical compliance, operations, and quality assurance, with a specialized focus on driving innovation and efficiency in cell therapy manufacturing. With over two decades of dedicated service in the biopharmaceutical industry, most recently serving as the Head of GMP Manufacturing at the Astellas Institute of Regenerative Medicine, Carlos provided profound insights into the pivotal role of phase-appropriate quality systems in managing drug development from research to commercialization. Our discussion focused on how these systems facilitate the rapid delivery of treatments to patients in urgent need. Discussion points include: Defining Phase-Appropriate Quality Systems: Carlos detailed these systems as strategic frameworks designed to adapt to the requirements of different stages of drug development, emphasizing their critical role in accelerating the development process. Regulatory Framework and Impact: Insights into how FDA guidelines are tailored to expedite the transition from laboratory research to market, highlighting the regulatory nuances that allow for such flexibility. Handling Variability in Drug Development: Strategies for managing the inherent variability in early development phases were discussed. Carlos emphasized the necessity of flexible, responsive quality systems that facilitate quick adaptations. Analytical Testing and Development Oversight: Carlos explored the significant role of analytical testing in early phases, focusing on controlling and understanding variability to improve assay development continuously. Challenges in Preclinical to Clinical Transition: He underscored the importance of maintaining consistency in the quality of preclinical materials to ensure seamless progression into clinical trials. Importance of Effective Change Control Systems: The conversation covered how early-stage quality systems should anticipate and manage frequent changes to support rapid learning and adaptation. Strategic Approach to Quality System Design: Carlos discussed designing quality systems that reflect the company's risk tolerance and the urgency of patient needs, effectively balancing speed, cost, and compliance. Future Trends in the Life Sciences Sector: Carlos provided predictions on the evolution of quality systems to meet the dynamic needs of ongoing and future drug development projects. Carlos Yuraszeck is a distinguished leader in biopharmaceutical compliance, operations, and quality assurance, specializing in cell therapy manufacturing. Over his extensive career spanning more than two decades, Carlos has significantly impacted the biopharmaceutical industry through his leadership in various pivotal roles. As the Executive Director of GMP Operations at Astellas Pharma US, he led the transformation of research groups into fully operational GMP manufacturing facilities. Earlier, as Senior Vice President of Technical Operations at Talaris Therapeutics, he managed operations focused on groundbreaking organ transplantation therapies. At Celgene, Carlos directed clinical production and supply, where he scaled up manufacturing operations to support the delivery of life-saving CAR T-cell therapies. His tenure in the industry is marked by a commitment to excellence, deep regulatory knowledge, and strategic oversight, which have driven the successful development and commercialization of novel therapies. Carlos's leadership style emphasizes collaboration, transparency, and continuous learning, aiming always to enhance patient outcomes and advance the field of biopharmaceuticals through innovative and efficient manufacturing practices.

Der er fuldt knald på stamcelleforskningen i disse år!  Lige nu er tre forskergrupper i Japan, USA og vores broderland Sverige i fuld gang med at udvikle stamcellebehandlinger, der skal hjælpe Parkinsons-patienter.  I dagens episode af Brainstorm dykker Nana og Anne Sophie derfor ned i, hvordan stamceller kan hjælpe på Parkinsons-patienters ryste-symptomer, og hvorfor behandlingen tager så pokkers lang tid at udvikle...  Forskere har nemlig været i gang med at lave forskellige typer af celleterapi i flere år, men vi har stadig til gode at kunne blive behandlet med stamceller på hospitalet.  Så, hvornår kommer behandlingen? Hvordan fungerer den? Og hvad er de største udfordringer på vejen mod stamceller? Det spørgsmål stiller værterne til Josefine Rågård Christiansen. Hun er nemlig en af de forskere, der har haft fingrene godt nede i de svenske forsøg.  Brainstorm er støttet af Lundbeckfonden. Følg Brainstorm på Instagram. Medvirkende: Josefine Rågård Christiansen, ph.d.-studerende, Novo Nordisk Foundation Center for Stem Cell Medicine, Københavns Universitet Redaktion:  Anne Sophie Thingsted, Nana Elving Hansen, Astrid Marie Wermus, Caroline Overskov Links: Studie, der gik forud for klinisk forsøg med en ny stamcelle-baseret terapi til behandling af Parkinson's sygdom i Sverige: ‘Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD', Cell Stem Cell, 2023 Prækliniske studier, der har gået forud for, at myndigheder har godkendt menneskeforsøg med Parkinson's patienter:  Amerikansk studie: ‘Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product', MSK-DA01, Cell Stem Cell, 2021 Japansk studie: ‘Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease', Nature Communications, 2020 Review-artikel om succeser og udfordringer med udvikling af stamcelleterapi: ‘Clinical translation of pluripotent stem cell-based therapies: successes and challenges', Stem Cells & Regeneration, 2024. Musik: ‘Stem Cells - Science Revision Song' af Hannah's Science World på YouTube

The transition from learning in an undergraduate or graduate program to learning in medical school is a big one, and some may wonder the reasoning behind the structures of a medical school didactic curriculum. In this insightful episode, Griffin engages in a discussion with Dr. Gregory Gruener, Vice Dean for Education at Loyola University Chicago Stritch School of Medicine, delving into the intricacies of preclinical curriculum design. Dr. Gruener sheds light on the in-depth process of curriculum development, elucidates the underlying principles, and explains the challenges posed by recent changes to the USMLE Step 1. Listen as they explore Dr. Gruener's goals for the future of medical education and his aspirations to personalize the learning experience for medical students. Episode produced by: Griffin K Johnson Episode recording date: 01/05/2024 www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate --- Send in a voice message: https://podcasters.spotify.com/pod/show/medicus/message

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered research showing that a lower dose of an anti-emetic drug could have similar efficacy — and fewer side effects — than the standard, higher dose.  NCCN Guidelines Give Framework for Childhood Neuroblastoma Treatment The National Comprehensive Cancer Network recently published guidelines for the treatment of pediatric patients with neuroblastoma. This resource is geared toward mitigating unnecessary side effects and over treatment in patients with low-risk disease, while also developing the best treatment plans for high-risk patients.  CURE® spoke with Dr. Rochelle Bagatell, professor of Pediatrics and Solid Tumor Section Chief at Children's Hospital of Philadelphia, and Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Neuroblastoma, who emphasized that while these guidelines can influence treatment strategies, conversations between patient families and clinicians and even insurance coverage, each patient's care should be as personalized as possible.  “There may be specific cases where the nuances of a particular patient's case means that you have to adjust your thinking from what's written on those nice, clear lines,” Bagatell said. “But the general guidance about how to think about the risk of recurrence, what general type of therapy would be appropriate, how much chemotherapy when to do surgery. Those are the kinds of things that patients and families can look at and bring to their doctor and discuss.” FDA Fast Tracks ARV-471 for Metastatic Breast Cancer Last week the Food and Drug Administration (FDA) granted a Fast Track designation to ARV-471, a novel drug being studied for the treatment of patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Specifically, this indication of ARV-471 is for patients who previously underwent endocrine therapy.  Fast Track designations are given to drugs that show promise in treating serious conditions and fill an unmet need. The goal is to speed up the review and potential approval of these therapies.  ARV-471 is being studied in the phase 3 VERITAC-2 clinical trial, which is comparing ARV-471 to Faslodex in this patient population. Preclinical studies showed that the drug induced tumor shrinkage and degradation.  FDA Grants Priority Review for Alecensa in Some ALK-Positive NSCLC Also in FDA news from last week, the agency granted a priority review to Alecensa as a postsurgical treatment for patients with early-stage ALK-positive non-small cell lung cancer.  The priority review is based off findings from the phase 3 ALINA trial, which showed that the drug led to a 76% reduction in the risk of disease recurrence or death compared with chemotherapy treatment. Findings from this study also showed that at two years, 93.8% of patients taking Alecensa experienced disease-free survival (which is the time after treatment when patients do not have symptoms of complications from their cancer), compared with 63% in the chemotherapy group. At three years, disease-free survival rates were 88.3% and 53.3%, respectively.  With the priority review, the FDA said that they plan on making an approval decision on Alecensa on or by May 22, 2023, though those dates can always change.  Lower Dose of Nausea, Vomiting Drug Controls Chemo Symptoms Finally, research showed that a lower dose of a nausea and vomiting drug could be just as effective as the higher, standard dose when it comes to controlling chemotherapy-induced nausea and vomiting.  A study published in The Lancet Oncology found that a 2.5-milligram dose of olanzapine is not inferior (meaning it is no less effective) than a 10-milligram dose. Specifically, the researchers looked at the use of rescue medications, vomiting episodes and mild nausea over the course of 120 hours.  Notably, this lower dose can also lead to a decrease in side effects related to the drug, such as feeling of lethargy and drowsiness.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

BUFFALO, NY- February 7, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.” In this new paper, researchers Ashley Del Dosso, Elizabeth Tadevosyan, and James R. Berenson from ONCOtherapeutics, Berenson Cancer Center, and Institute for Myeloma and Bone Cancer Research discussed multiple myeloma (MM) — the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of this B-cell malignancy. These new drugs have often been evaluated together and in combination with older agents. However, even these novel combinations eventually become ineffective; and, thus, novel therapeutic approaches are necessary to help overcome resistance to these treatments. Recently, the Janus Kinase (JAK) family of tyrosine kinases, specifically JAK1 and JAK2, has been shown to have a role in the pathogenesis of MM. Preclinical studies have demonstrated a role for JAK signaling in direct and indirect growth of MM and downregulation of anti-tumor immune responses in these patients. Also, inhibition of JAK proteins enhances the anti-MM effects of other drugs used to treat MM. These findings have been confirmed in clinical studies which have further demonstrated the safety and efficacy of JAK inhibition as a means to overcome resistance to currently available anti-MM therapies. Additional studies will provide further support for this promising new therapeutic approach for treating patients with MM. “The following sections of this article will be focused on studies of RUX [Ruxolitinib] in the preclinical [21–24] and clinical settings [18–20] focused on the treatment of relapsed/refractory (RR) MM.” DOI - https://doi.org/10.18632/oncotarget.28547 Correspondence to - James R. Berenson - jberenson@berensoncancercenter.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28547 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, multiple myeloma, ruxolitinib, JAK/STAT, cytokine, clinical trial About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In this ToxChats© episode, we interview Dr. Chris Christou, Director of Preclinical Imaging and Research Laboratories at the South Australian Health and Medical Research Institute. Dr. Christou discusses the history of sheep as a preclinical species for medical device testing, novel groundbreaking neurological disease models, and the use of sheep as an alternative model in general toxicology studies. Critical regulatory standards and international guidelines are discussed to ensure successful submissions with the US Food and Drug Administration, the Australia Therapeutic Goods Administration, and the Australia New Zealand Therapeutic Products Agency.

Duas torres de transmissão parecem usar seus cabos como se fossem cordas. Uma terceira torre parece "pular corda". Toda vez que ela pula, a imagem treme... E algumas pessoas conseguem "ouvir" um som! E você, "ouve" algo? A ciência explica esse fenômeno?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.> OUÇA (44min 59s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*PARCERIA: ALURASabe quem mais chegou com 2024? A primeira Imersão Front-End da Alura, perfeita para começar o ano se aprofundando em tecnologia.Em 5 aulas gratuitas, você vai mergulhar em HTML, mergulhar em CSS e criar uma página web responsiva e com layouts avançados. É 100% online, 100% gratuito e com certificado de participação, com a melhor didática e as melhores professoras e professores.Você ainda terá acesso gratuito à Luri, a IA da Alura, e vai interagir com a comunidade Dev e aproveitar o espaço para networking no Discord.Mais de um milhão de pessoas já mergulharam nas Imersões da Alura. Chegou a sua vez de explorar esse novo universo. Então faça sua inscrição grátis agora mesmo, porque as vagas são limitadas!alura.tv/naruhodo-imersaofrontend*REFERÊNCIASTuíte Original (12/2017)https://x.com/LisaDeBruine/status/937105553968566272A deafening flash! Visual interference of auditory signal detectionhttps://www.sciencedirect.com/science/article/pii/S1053810016303336?via%3DihubModality effects in the coding reproduction of rhythmshttps://link.springer.com/article/10.3758/BF03202611Sounds from seeing silent motion: Who hears them, and what looks loudest?https://www.sciencedirect.com/science/article/abs/pii/S0010945218300741Neurocognitive mechanisms of synesthesiahttps://pubmed.ncbi.nlm.nih.gov/16269367/Expectancies and the generation of perceptual experience: Predictive processing and phenomenological controlhttps://osf.io/preprints/psyarxiv/rjn3kHearing through Your Eyes: Neural Basis of Audiovisual Cross-activation, Revealed by Transcranial Alternating Current Stimulationhttps://direct.mit.edu/jocn/article-abstract/31/6/922/29031/Hearing-through-Your-Eyes-Neural-Basis-of?redirectedFrom=fulltextChapter 18 - Psychophysical and behavioral peripheral and central auditory testshttps://www.sciencedirect.com/science/article/abs/pii/B9780444626301000184From oppressiveness to stress: A development of Stress Reduction Theory in the context of contemporary high-density cityhttps://www.sciencedirect.com/science/article/pii/S0272494422001281?casa_token=tByMbwrf9pQAAAAA:E1ryVic2p1ma-p3u60KHQQvdaMhu_QVjp0378LVX8eSCFLEX9Z6JLOi1m5FaPMdcV72R9D-huUgSilence in the consumer experience: A conceptualization and research agendahttps://www.sciencedirect.com/science/article/pii/S0148296323003910?casa_token=3HI5ATTO9RoAAAAA:Ye-D9YXFjitUfVfK69VYtFAn0KaTdgEifLXLqE4XiG8KGrwQiM_bjoDWAku693jrXCVFjvoCo60The Diversity of Strategies Used in Working Memory for Colors, Orientations, and Positions: A Quantitative Approach to a First-Person Inquiryhttps://onlinelibrary.wiley.com/doi/full/10.1111/cogs.13333Hearing what you see: Distinct excitatory and disinhibitory mechanisms contribute to visually-evoked auditory sensationshttps://www.sciencedirect.com/science/article/pii/S0010945220302732?casa_token=fM-wF61tH7QAAAAA:U5V7vEtQ8gK9dR_Y0NIW_rmoQ4wbgWsuEufULaurgeaKWX2KOlWIN9yQaoUbtsTiBXe-hXCrkNkGreat expectations! How predictions about the magnitude of a forthcoming sound affect its perceptual and neural processinghttps://unsworks.unsw.edu.au/entities/publication/87b67f42-bb63-4935-8cf9-688c36809cac/fullBioelectronic medicine: Preclinical insights and clinical advanceshttps://www.cell.com/neuron/pdf/S0896-6273(22)00808-X.pdfExpected Experiences - The Predictive Mind in an Uncertain Worldhttps://www.taylorfrancis.com/books/edit/10.4324/9781003084082/expected-experiences-tony-cheng-jakob-hohwy-ryoji-satoExemplo Som Código Morsehttps://www.youtube.com/watch?v=Pz57ov1pV4MNaruhodo #270 - O que é e como se dá a sinestesia?https://youtu.be/fvfrWcEEDco?si=wmdegsj6KfcainaPNaruhodo #296 - Todas as pessoas imaginam as coisas do mesmo jeito?https://youtu.be/ZcNZ92bTZc4?si=_ImAQuNXIpp2jYI6Naruhodo #29 - O que é e como acontece o déjà vu?https://youtu.be/MsgpP0CWrZs?si=IvJ17lCAH8rTJLe0*APOIE O NARUHODO PELA PLATAFORMA ORELO!Um aviso importantíssimo: o podcast Naruhodo agora está no Orelo: https://bit.ly/naruhodo-no-oreloE é por meio dessa plataforma de apoio aos criadores de conteúdo que você ajuda o Naruhodo a se manter no ar.Você escolhe um valor de contribuição mensal e tem acesso a conteúdos exclusivos, conteúdos antecipados e vantagens especiais.Além disso, você pode ter acesso ao nosso grupo fechado no Telegram, e conversar comigo, com o Altay e com outros apoiadores.E não é só isso: toda vez que você ouvir ou fizer download de um episódio pelo Orelo, vai também estar pingando uns trocadinhos para o nosso projeto.Então, baixe agora mesmo o app Orelo no endereço Orelo.CC ou na sua loja de aplicativos e ajude a fortalecer o conhecimento científico.https://bit.ly/naruhodo-no-orelo

Matthew and Lowell discussed the development of a new DNA targeting intervention to clear senescent cells. They highlighted the unique approach of Oisin, which targets cells based on their transcriptional activity rather than their appearance or behavior. The conversation also touched on the challenges of DNA delivery, the potential for future adaptations to target new pathways, and the advantages of their non-viral vector. Matthew shared his journey into biotech, developing an app store for the human body, and the shift in the field's perception of his idea. The conversation ended with a discussion on the potential of using machine learning and control in building therapies that would have been difficult in the past. https://youtu.be/2JKgtNWXO1c PODCAST INFO: The Learning With Lowell show is a series for the everyday mammal. In this show we'll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn't normally ever get to hear. The Host of the show – Lowell Thompson- is a lifelong autodidact, serial problem solver, and founder of startups. LINKS Spotify: https://open.spotify.com/show/66eFLHQclKe5p3bMXsCTRH RSS: https://www.learningwithlowell.com/feed/podcast/ Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q Youtube clips: https://www.youtube.com/channel/UC-B5x371AzTGgK-_q3U_KfA Website: https://www.learningwithlowell.com Matthew Scholz links https://www.immusoft.com/people/matthew-scholz/ https://www.linkedin.com/in/matthewscholz https://www.oisinbio.com/ Timestamps 01:30 DNA Targeting Intervention for Senescent Cells 10:00 Business Model and Teamwork in Biotech 16:00 Immune System App Store Conceptualization 19:00 Bio App Store Journey: From Skepticism to Acceptance 27:00 Team's Journey: Overcoming Challenges, Securing Funding 36:00 Seed Rounds in Biotechnology: Simplified and Protective 39:00 Senescent Cell Therapies and Brain Health 47:00 Preclinical to Clinical Challenges and Animal Testing Concerns 53:00 Targeted Biological Research Challenges 57:00 Machine Learning in Therapy Development 1:00:00 Schwarzenegger Mice: Benefits and Risks in Therapy and Metabolic Health 1:10:00 Foundations, Research, and Synthetic Biology 1:15:00 Where He needs help

In this podcast, Nirmish Shah, MD, discusses an overview, the results, and the preclinical and clinical impact of the study titled Preclinical and Clinical Use of AB1, a DNMT1 Protein Depleter, to Upregulate Fetal Hemoglobin in Townes Sickle Cell Disease (SCD) Mice and Patients with SCD. Dr Shah also presented on this topic at the American Society of Hematology's 2023 annual meeting in San Diego, CA.

I tell my students that we are constellations of our peers, mentors, and patients. What we learn from each other in preclinical education—spanning not just facts and answers, but also how we treat each other—will shape the future of medicine. Brian R. Smith reflects on creating a learning culture that is safe and empowering for students instead of humiliating. The essay read in this episode was published in the Teaching and Learning Moments column in the November 2023 issue of Academic Medicine. Read the essay at academicmedicine.org.

In this issue, we will review the applications of PCR analysis for your gene therapy programs, and present two case studies. Click to read this audiobook: https://www.altasciences.com/sites/default/files/2023-10/the-altascientist-issue-37-pcr_4.pdf Gene therapy continues to accelerate through preclinical and clinical research arenas. These programs are developed with targeted and personalized medicines in mind. The goal of gene therapy is to safely deliver and incorporate a genetic alteration to restore or repair the protein of a missing or faulty gene. Preclinical assessments of gene therapies consider the general absorption, distribution, metabolism, and excretion of the drug, as well as data from tailored assessments to evaluate delivery and cell incorporation. Gene therapies require, by design and definition, DNA and/or RNA delivery and analysis. While most ongoing research involves gene therapies being delivered in vivo via adeno-associated viral (AAV) vectors, new in vivo delivery mechanisms are on the rise, such as other types of delivery vectors including lipid nanoparticles. CHAPTESR: - 0:05 — About Issue 37 - 1:20 — Introduction to qPCR, dPCR, and RT-PCR - 5:58 — Utility of qPCR, ddPCR, and RT-PCR - 8:19 — PCR Applications - 10:01 — Advantages and Applications - 17:45 — Case Study 1 - 20:20 — Case Study 2 - 22:47 — Conclusion About Altasciences: Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Today we have Juliette Audet with us. Juliette is a Partner at Forbion a multi-stage venture fund in Amsterdam and Munich backing biotech companies in Europe and North America to impact the future of medicine.Forbion is investing out of 2 separate funds: Forbion Ventures Fund VI and Forbion Growth Opportunities Fund II, of €750M and €600M respectively, with a total of 3b EUR AUM and an established portfolio of 44 companies, with notable investment including NewAmsterdam Pharma, Gyroscope and Inflazome. At Forbion, Juliette focuses on the Venture strategy, investing in biotech companies from pre-clinical stage to Phase 1b and led the investments in NewAmsterdam Pharma, Mestag and Dualyx amongst others.Jump to the parts that matter most to you

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D.Her guests include:Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics   Michael Tsipursky, MD, CEO and Cofounder of Revive BiotechMichael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology's BEHOLD trialSamarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope TherapeuticsOptigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What's next?Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles?Dr. Singer is a principal investigator in Unity Biotechnology's clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies.Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light?Tune in to hear today's experts discuss:How Optigo plans to extend the duration of afliberceptThe impact of extending duration activity on patients, physicians, and payersWhat Optigo plans to accomplish over the next 12 monthsWhat's behind Revive Biotech's proprietary technology and what makes it unique.The milestones it has completed so far with relation to clinical trials, intellectual property, and fundingThe new class of therapeutics being developed by Unity BiotechnologyThe data released so far on the UBX-1325 BEHOLD trialIf approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practiceThe potential impact of Nanoscope Therapeutics's MCO-010 on patient communitiesThe feedback reported from clinical trial participantsThe critical milestones Nanoscope Therapeutics intends to achieve over the next year[Listen Now]

How is academia fostering research that later turns into startup companies? What are new computational powers bringing to in silico drug design? And what is MoveableType methodology and why should pharma be excited about it? We will learn those answers and more in this episode with Lance Westerhoff, President and General Manager of QuantumBio. QuantumBio is a biotech startup operating in the vast field of drug discovery and molecular design. As President and GM, Lance oversees QuantumBio's day-to-day management including the research, development, and deployment of advanced technology, as well as strategic partnerships and business development. Lance earned his PhD in Chemistry at Penn State University, and he is an entrepreneur, computational biochemist, and published scientist with projects involving the synergistic application of quantum mechanics and molecular mechanics in the life and pharmaceutical sciences. QuantumBio recently earned a Small Business Innovation Research (SBIR) grant from the NIH to run calculations for their MovableType methodology research, which they will be working with Oracle on that research project, and we talk about that and much more in this episode.  

Join Drs Amelia Langston and Frederick Locke as they discuss the future of CAR T-cell therapy research and treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987070). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Adoptive Cell Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adoptive-cell-therapy Graft Versus Host Disease (GVHD) https://emedicine.medscape.com/article/429037-overview Multiple Myeloma https://emedicine.medscape.com/article/204369-overview BCMA in Multiple Myeloma-A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/ Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-shelf" T Cell Therapy Using iPSC Technology and Gene Editing https://pubmed.ncbi.nlm.nih.gov/35053386/ Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34466048/ Preclinical and Clinical Studies of CAR-NK-cell Therapies for Malignancies https://pubmed.ncbi.nlm.nih.gov/36353643/ How I Treat Cytopenias After CAR T-cell Therapy https://pubmed.ncbi.nlm.nih.gov/36800563/ T-cell Receptor-based Therapy: An Innovative Therapeutic Approach for Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34193217/ Biochemistry, HLA Antigens https://www.ncbi.nlm.nih.gov/books/NBK546662/ CAR T-cell Cancer Therapy Targeting Surface Cancer/Testis Antigens https://pubmed.ncbi.nlm.nih.gov/32983080/ Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges https://pubmed.ncbi.nlm.nih.gov/36077696/ Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/ Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/

A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.” In their new perspective, researchers Daniel Morillo, Gala Vega and Victor Moreno from Hospital Fundación Jiménez Díaz discuss Cyclin-dependent kinases (CDK) in hematological malignancies. CDKs belong to a family of serine/threonine kinases that need to form heterodimeric complexes with cyclins to perform their functions. These kinases are involved in multiple processes within cells, including cell cycle, apoptosis, transcription and differentiation. These kinases are often overexpressed in different malignancies, making them potential targets for new drugs. Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors suppress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first in-human trial, enitociclib demonstrated clinical activity in a small cohort of patients with high grade B lymphoma with MYC and BCL2 and/or BCL6 rearrangements, inducing complete responses in 2 of 7 subjects (29%) in monotherapy. “In summary, most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC and MCL1. CDK9 inhibitors are relatively new drugs that inhibit transcription of these anti-apoptotic and pro-survival proteins.” DOI - https://doi.org/10.18632/oncotarget.28473 Correspondence to - Victor Moreno - victor.moreno@startmadrid.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28473 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cyclin-dependent kinases (CDK), CDK9, hematological malignancies About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Listen in as experts discuss the advantages of an integrated approach supporting drug development from discovery to commercialization.

Questions for Cristian? He's kindly offered his email address for outreach : cristian.fernandez@unibe.chor reach out to him on LinkedIn: https://www.linkedin.com/in/fernandez-palomo/ 

A look back at the first two years of medical school, the preclinical curriculum, including advice on how to excel in courses as well as managing relationships in medical school.

The field of biomarkers is advancing quickly, allowing preclinical Alzheimer's disease to be identified earlier and earlier in a person's life. As individuals learn they are at risk for Alzheimer's years or even decades before experiencing cognitive decline, what does this mean for them and for society as a whole? Drs. Emily Largent and Claire Erickson join the podcast to discuss ten key areas, such as healthcare, insurance, and direct-to-consumer testing, that should be addressed to support those at risk for cognitive decline and broader U.S. society as biomarker testing and disclosures become more prominent. Guests: Emily Largent, PhD, RN, Emanuel and Robert Hart Assistant Professor, University of Pennsylvania Perelman School of Medicine, and Claire Erickson, PhD, MPA, postdoctoral fellow, University of Pennsylvania Perelman School of Medicine Show Notes Read Drs. Emily Largent and Claire Erickson's paper, “Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society,” on PubMed Central.  Learn more about Dr. Largent at her bio on the Penn Leonard Davis Institute of Health Economics website. Learn more about Dr. Erickson at her bio on the Penn Leonard Davis Institute of Health Economics website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Despite public market investors shying away from preclinical companies amid biotech's bear market, large biopharmas have ramped up their deal making for early-stage assets and technologies and are willing to pay for access to new modalities, says BioCentury's Stephen Hansen on the latest BioCentury This Week podcast. Hansen and colleagues also discuss the implications of FDA's approval of gene therapy Zynteglo from bluebird bio Inc., and the latest advances and leaders in the field of epigenome editing.

In our latest episode, we welcome Dr. Mikael Sodergren, Medical Cannabis Research Group Lead at Imperial College London and Managing Director at Sapphire Medical Clinics.We examine how clinical trials and real-world evidence can be used to prove the efficacy of cannabis-based medicines, as well as the challenges associated with applying traditional licensing and regulatory models to these novel medicines.

Commentary by Dr. Valentin Fuster